Abelacimab clinical trials
Also written MAA868.
How each study uses abelacimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the abelacimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2022 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Anthos Therapeutics, Inc. (5) · Novartis Pharmaceuticals (3)
Studies
Open first, then newest update. How each study uses abelacimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AnticoagulationNot yet recruitingPhase 3Novartis PharmaceuticalsNCT07739888Written as Abelacimab
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)RecruitingPhase 3Anthos Therapeutics, Inc.NCT05712200Written as Abelacimab
- A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTETerminatedPhase 3Anthos Therapeutics, Inc.NCT05171075Written as Abelacimab
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTETerminatedPhase 3Anthos Therapeutics, Inc.NCT05171049Written as Abelacimab
- Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial FibrillationActive, not recruitingPhase 2Anthos Therapeutics, Inc.NCT04755283Written as Abelacimab
- A Dose-range Finding Study of MAA868 in Patients With Atrial FibrillationCompletedPhase 2Anthos Therapeutics, Inc.NCT04213807Written as MAA868 Cohort 1
- Prevention of Thromboembolic Events in Total Knee Replacement PatientsWithdrawnPhase 2Novartis PharmaceuticalsNCT03393481Written as MAA868
- Efficacy and Safety of MAA868 in Patients With Atrial FibrillationWithdrawnPhase 2Novartis PharmaceuticalsNCT03398434Written as MAA868
Codes
What other systems call abelacimab · ClinicalTrials.gg INT001701
- MeSH (NLM) C000718976abelacimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KX1N4TV7UYABELACIMABConfirmed FDA, NLM
- NCI Thesaurus C169755AbelacimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718976 | abelacimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KX1N4TV7UY | ABELACIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C169755 | Abelacimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.